Abstract
Although initially effective against metastatic colorectal cancer (CRC), irinotecan-based chemotherapy leads to resistance and adverse toxicity. Curcumin is well known for its anti-cancer effects in many cancers, including CRC. Here, we describe reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress as important mechanisms by which curcumin enhances irinotecan's effects on CRC cells. CRC cell lines were treated with curcumin and/or irinotecan for 24 h, and then evaluated using cell proliferation assays, cell apoptosis assays, cell cycle analysis, intracellular Ca2+ measurements, ROS measurements and immunoblotting for key ER stress-related proteins. We found that cell viability was inhibited and apoptosis was increased, accompanied by ROS generation and ER stress activation in CRC cells treated with curcumin alone or in combination with irinotecan. Blocking ROS production attenuated the expression of two markers of ER stress: binding of immunoglobulin protein (BIP) and CCAAT/enhancer-binding protein homologous protein (CHOP). Blocking CHOP expression using RNA interference also inhibited ROS generation. These results demonstrated that curcumin could enhance the effects of irinotecan on CRC cells by inhibiting cell viability and inducing cell cycle arrest and apoptosis, and that these effects may be mediated, in part, by ROS generation and activation of the ER stress pathway.
Highlights
Colorectal cancer (CRC) is one of the most common cancers, and is the fourth leading cause of cancer-related death globally
These results suggested that curcumin with irinotecan caused further inhibition of growth in both LoVo and HT-29 colorectal cancer (CRC) cell lines
These results suggested that blocking endoplasmic reticulum (ER) stress suppresses reactive oxygen species (ROS) production induced by curcumin alone or combined with irinotecan, and that ROS generation might be promoted by severe ER stress in CRC cells
Summary
Colorectal cancer (CRC) is one of the most common cancers, and is the fourth leading cause of cancer-related death globally. The 5-year survival rate of patients with CRC metastasis is less than 10% [1]. Chemotherapy is an effective treatment for metastasized CRC, as is irinotecan, a derivative of natural camptothecin. Irinotecan alone or in combination with chemotherapy improve survival rates of patients with advanced CRC [2, 3]. Irinotecan and its active form, 7-ethyl 10-hydroxycamptothecin (SN-38), inhibit DNA topoisomerase, which induces a permanent DNA double-strand break and results in a DNA damage response (DDR). Despite the efficacy of irinotecanbased chemotherapy for CRC patients, these treatments lead to dose-dependent enterotoxigenesis and acquired chemoresistance. Novel and safe treatment strategies to overcome drug resistance and minimize side effects are needed to improve CRC treatment
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have